 |
|
|
|
 |
|
|
| Article 1 to 7 out of 7 concerning Biosite Inc.
|
-
Oxford Genome Sciences announces new Therapeutic Antibody Deal with Medarex
(20 Sep 2007)
New agreement to drive the development of OGeS' own pipeline of antibodies in cancer
Oxford Genome Sciences (UK) Ltd (OGeS) announced a second partnering agreement with Medarex, Inc. This new agreement provides OGeS with broad access to Medarex's fully human antibody technology and will potentially enable OGeS to accelerate the ...
-
Beckman Coulter Announces Additional Details on Financing for Its Proposed Acquisition of Biosite Incorporated
(17 Apr 2007)
Beckman Coulter, Inc. announced additional details regarding its financing strategy for the proposed acquisition of Biosite Incorporated. On March 25, 2007, Beckman Coulter announced it had entered into a definitive merger agreement with Biosite ...
-
Biosite Prepared to Enter Into Discussions With Inverness Medical Innovations
(12 Apr 2007)
Biosite Incorporated announced that its Board of Directors, after consultation with its financial and legal advisors, has determined that the acquisition proposal set forth in the letter received from Inverness Medical Innovations, Inc. on April 4, ...
-
Beckman Coulter to Acquire Biosite Incorporated
(27 Mar 2007)
Beckman Coulter, Inc. and Biosite(R) Incorporated announced that they have entered into a definitive merger agreement under which Beckman Coulter will acquire all of Biosite's outstanding common stock in a cash tender offer of $85.00 per share, or ...
-
Biosite and Oxford Genome Sciences announce collaboration in colorectal cancer
(07 Apr 2006)
Biosite Incorporated and Oxford Genome Sciences (UK) Ltd. (OGeS) announced a collaboration for the evaluation of protein-based disease markers for colorectal cancer. The markers could be used for the development of potential blood-based diagnostic ...
-
Lilly and Biosite to Collaborate on Clinical Trial Using Tailored Xigris Therapy
(22 Mar 2006)
Trial to Study Use of Biomarker to Better Define Xigris Patients and Treatment Response
Eli Lilly and Company and Biosite® Incorporated announced the two companies have signed an agreement to collaborate in connection with a clinical trial employing a tailored therapy strategy for Lilly's severe sepsis drug, Xigris® (drotrecogin alfa ...
-
Biosite and FivePrime Announce Antibody Collaboration
(23 Feb 2006)
Biosite Incorporated and Five Prime Therapeutics, Inc. have entered into a collaboration for the evaluation of disease targets for potential commercialization of diagnostic and therapeutic products.Under the collaboration, FivePrime will provide ...
|
|
|
|
|
Top
